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(attendance) of this programme proved to be low. Therefore we
aimed to analyze the frequency and distribution of Papanicolau
smears. METHODS: The data were derived from the ﬁnancial
database of the National Health Insurance Fund Administration
(OEP) of Hungary covering the period of 2003–2005. First we
calculated the frequency of pap smears then the distribution
according to geographical regions. Screening is deﬁned with the
cytological examination of Papanicolau smear and includes all
smears taken either within or outside of the organized pro-
gramme. RESULTS: The age speciﬁc screening rate of women
aged 25–64 years was 52,65% in 2003–2005. Distribution of
Papanicolau smears according to regions was: Central-Hungary:
28,4%, Central-Transdanubia: 10,5%, Western-Transdanubia:
9,3%, Southern-Transdanubia: 10,8%, Northern-Hungary:
13,2%, Northern-Greatplane: 14,2%, Southern-Greatplane:
13,6%. Frequency (number) of Papanicolau smears per 10.000
female population according to regions: Central-Hungary: 4685,
Central-Transdanubia: 4540, Western-Transdanubia: 4571,
Southern-Transdanubia: 5257, Northern-Hungary: 5035,
Northern-Greatplane: 4651, Southern-Greatplane: 4899. CON-
CLUSION: We found signiﬁcant inequalities in the frequency of
Papanicolua smears was the highest in the Southern-Transdanu-
bian and Northern-Hungarian regions. To increase participation
rate and to decrease within country inequalities are inportant
aims of the Hungarian nationwide organized cervical cancer
screening program.
PCN38
WITHIN COUNTRY DIFFERENCES IN MAMMOGRAPHY
COVERAGE OF THE HUNGARIAN NATIONWIDE ORGANIZED
BREAST CANCER SCREENING PROGRAMME
Boncz I1, Sebestyén A1, Döbrõssy L2, Budai A2, Kovács A2, Ember I3
1National Health Insurance Fund Administration, Budapest, Hungary,
2National Public Health and Medical Ofﬁcers Service (ÁNTSZ),
Budapest, Hungary, 3University of Pécs, Pécs, Hungary
OBJECTIVES: Nationwide organized breast cancer screening
programme was launched 2002 in Hungary for women between
the age of 45–65 with a 2 years screening interval. The aim of
the study is to analyse the within country inequalities of mam-
mography coverage of the organized programme. METHODS:
Data derive from the database of the National Health Insurance
Fund Administration (OEP) containing routinely collected ﬁnan-
cial data. The study includes all the women aged 45–64 hav-
ing either screening or diagnostic mammography before
(2000–2001) and after (2002–2003 and 2004–2005) the intro-
duction of organized screening. The regional inequalities are cal-
culated for 19 counties and Budapest as the capital (altogether
20 items). Coverage is deﬁned as the proportion of women res-
ident who have had a mammogram at least once in the previous
2 years. RESULTS: National mammography coverage was
26.7%, 54,6% and 51,6% in 2000–2001, 2002–2003 and
2004–2005 respectively. We found the highest coverage in
2000–2001 in counties having earlier pilot screening pro-
gramme: county Tolna (59.2%), county Jász-Nagykun-Szolnok
(45.1%), county Zala (39.5%). After the introduction of nation-
wide breast screening programme in 2002–2003 we found the
highest coverage in the following counties: county Szabolcs-
Szatmár-Bereg 70.8%, county Borsod-Abaúj-Zemplén 64.4%,
county Veszprém 63.9%. In 2004–2005, the following counties
received the highest coverage: county Gyõr-Moson-Sopron
(60.8%), county Szabolcs-Szatmár-Bereg 58.1% and county Vas
56.2%. The ratio of coverage between the counties with the
highest and lowest coverage was 3.5 (2000–2001), 2.6
(2002–2003) and 1.4 (2004–2005). CONCLUSION: We found
signiﬁcant within country differences in mammography cover-
age, however the gap between counties with lowest and highest
coverage became smaller after the introduction of organized
screening programme.
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OBJECTIVES: The aim of this study is to analyze and compare
the distribution of inpatient care treatment cost of and mortal-
ity due to breast cancer according to age-groups. METHODS:
Data derive from the database of the National Health Insurance
Fund Administration (OEP) containing routinely collected ﬁnan-
cial data. The study includes all the women who received out-
patient and/or inpatient care treatment in 2001 ﬁnanced from
public resources of OEP. Number of deaths due to breast cancer
is from the Central Statistical Ofﬁce database. We compared the
annual out- and inpatient care treatment cost and the annual
number of deaths according to the following age groups: 0–24,
25–44, 45–64, 65–74, 75+. RESULTS: The cost distribution of
out- and inpatient care treatment cost of breast cancer was the
following (outp./inp.): 0–24 years: 0.1%/0.2%; 25–44 years:
12.4%/11.7%; 45–64 years: 59.2%/59.1%; 65–74 years:
20.9%/20.2%; 75 and over: 7.4%/8.7%. The distribution of
deaths due to breast cancer was the following: 0–24 years: 0.0%;
25–44 years: 5.0%; 45–64 years: 37.0%; 65–74 years: 22.8%;
75 and over: 35.2%. We found that in the age-group 65–74 there
is a balance between the cost distribution (20.9% and 20.2%)
and the deaths (22.8%). Women in younger age groups received
more treatment cost than its mortality would predict, while in
older age groups (75+)—responsible 35.2% of deaths—received
only 7.4% and 8.7% of out- and inpatient treatment cost respec-
tively. CONCLUSION: There is a shift between the distribution
of treatment cost of and deaths due to breast cancer in favor of
younger age-groups.
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OBJECTIVES: Evidence guiding NSCLC treatment has been
derived largely from controlled trials at academic centers. Much
less attention has focused on understanding NSCLC treatment
by community-based oncologists. We undertook this study to
better understand NSCLC treatment patterns and outcomes in
community-based practices. METHODS: Ten large community-
based oncology practices in the U.S. were identiﬁed. Investiga-
tors conducted chart reviews on 417 NSCLC patients treated
with chemotherapy between 2001 and 2003 who were deceased
at the time of the review. RESULTS: Of the 417 patients (54%
male, median age 68 years, mean performance status 1.2) almost
20% had a history of radiation therapy, and 9.6% had a history
of surgery. Mean survival was 10.5 months for stage IIIB patients
(n = 114) and 7.9 months for stage IV patients (n = 303). In their
ﬁrst line of chemotherapy, 55% of patients received both carbo-
platin and paclitaxel (18% in combination with radiation
therapy). Another 11% received carboplatin with either gemc-
itabine (6%) or doctaxel (5%). In contrast, monotherapy was
more common in second line therapy (docetaxel 22%, gemc-
